Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer

References

• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47. doi:10.1093/annonc/mdr304.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer. 2011;117:1575–82. doi:10.1002/cncr.25660.
   PubMed Web of Science ®Google Scholar
• Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010;10:507. doi:10.1186/1471-2407-10-507.
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32. doi:10.1002/cncr.22381.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15:2302–10. doi:10.1158/1078-0432.CCR-08-2132.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–23. doi:10.1073/pnas.0932692100.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74. doi:10.1158/1078-0432.CCR-04-0220.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. doi:10.1038/nature11412.
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25. doi:10.1038/nature11404.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27:390–5. doi:10.1038/modpathol.2013.164.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7. doi:10.1038/nature11252.
   PubMed Web of Science ®Google Scholar
• Alvarez-Fischer D, Fuchs J, Castagner F, Stettler O, Massiani-Beaudoin O, Moya KL, Bouillot C, Oertel WH, Lombès A, Faigle W, et al. Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci. 2011;14:1260–6. doi:10.1038/nn.2916.
   PubMed Web of Science ®Google Scholar
• Alves dos Santos MT, Smidt MP. En1 and Wnt signaling in midbrain dopaminergic neuronal development. Neural Dev. 2011;6:23. doi:10.1186/1749-8104-6-23.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68. doi:10.1186/bcr2635.
   PubMed Web of Science ®Google Scholar
• Beltran AS, Graves LM, Blancafort P. Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene. 2014;33:4767–77. doi:10.1038/onc.2013.422.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31. doi:10.1007/s10549-009-0674-9.
   PubMed Web of Science ®Google Scholar
• Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One. 2011;6:e28403. doi:10.1371/journal.pone.0028403.
   PubMed Web of Science ®Google Scholar
• Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009;4:e6146. doi:10.1371/journal.pone.0006146.
   PubMed Web of Science ®Google Scholar
• Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, Cao L, Xiao PF, Pang L, Wu D, et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 2012;12:619. doi:10.1186/1471-2407-12-619.
   PubMed Web of Science ®Google Scholar
• Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota N. Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer. 2010;10:79. doi:10.1186/1471-2407-10-79.
   PubMed Web of Science ®Google Scholar
• Yang B, Jia L, Guo Q, Ren H, Hu D, Zhou X, Ren Q, Hu Y, Xie T. MiR-564 functions as a tumor suppressor in human lung cancer by targeting ZIC3. Biochem Biophys Res Commun. 2015;467:690–6. doi:10.1016/j.bbrc.2015.10.082.
   PubMed Web of Science ®Google Scholar
• Ma G, Dai W, Sang A, Yang X, Li Q. Roles of ZIC family genes in human gastric cancer. Int J Mol Med. 2016;38:259–66. doi:10.3892/ijmm.2016.2587.
   PubMed Web of Science ®Google Scholar
• Di Nardo AA, Nedelec S, Trembleau A, Volovitch M, Prochiantz A, Montesinos ML. Dendritic localization and activity-dependent translation of Engrailed1 transcription factor. Mol Cell Neurosci. 2007;35:230–6. doi:10.1016/j.mcn.2007.02.015.
   PubMed Web of Science ®Google Scholar
• Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci. 2001;21:3126–34.
   PubMed Web of Science ®Google Scholar
• Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, Dahia CL, Park-Min KH, Tobias JH, Kooperberg C, et al. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature. 2015;526:112–7. doi:10.1038/nature14878.
   PubMed Web of Science ®Google Scholar
• Bell D, Bell A, Roberts D, Weber RS, El-Naggar AK. Developmental transcription factor EN1–a novel biomarker in human salivary gland adenoid cystic carcinoma. Cancer. 2012;118:1288–92. doi:10.1002/cncr.26412.
   PubMed Web of Science ®Google Scholar
• Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016;48:265–72. doi:10.1038/ng.3502.
   PubMed Web of Science ®Google Scholar
• Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8:523–34. doi:10.1038/nrc2439.
   PubMed Web of Science ®Google Scholar
• Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, et al. Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur J Cancer. 2013;49:2214–22. doi:10.1016/j.ejca.2013.01.019.
   PubMed Web of Science ®Google Scholar
• Marszall MP, Sroka W, Adamowski M, Slupski P, Jarzemski P, Siodmiak J, Odrowąż-Sypniewska G.. Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination. Eur J Cancer Prev. 2015;24:51–6. doi:10.1097/CEJ.0000000000000046.
   PubMed Web of Science ®Google Scholar
• Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a candidate oncogene in human breast cancer. Oncogene. 2005;24:6890–901. doi:10.1038/sj.onc.1208840.
   PubMedGoogle Scholar
• Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123–33. doi:10.1634/theoncologist.2012-0397.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67. doi:10.1172/JCI45014.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
   PubMed Web of Science ®Google Scholar
• Weihua Z, Lin Q, Ramoth AJ, Fan D, Fidler IJ. Formation of solid tumors by a single multinucleated cancer cell. Cancer. 2011;117:4092–9. doi:10.1002/cncr.26021.
   PubMed Web of Science ®Google Scholar
• Staelens L, Van Poppel H, Vanuytsel L, Van Oosterom A, Van Damme B, Baert L. Sarcomatoid renal cell carcinoma: case report and review of the literature. Acta Urol Belg. 1997;65:39–42.
   PubMedGoogle Scholar
• Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621. doi:10.1016/0014-4827(61)90192-6.
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363–7. doi:10.1073/pnas.92.20.9363.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther. 2007;6:1684–90. doi:10.4161/cbt.6.11.5167.
   PubMed Web of Science ®Google Scholar
• Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene. 2014;33:116–28. doi:10.1038/onc.2013.96.
   PubMed Web of Science ®Google Scholar
• Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, et al. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Oncotarget. 2016;7:1796–807. doi:10.18632/oncotarget.6427.
   PubMed Web of Science ®Google Scholar
• Willis S, De P, Dey N, Long B, Young B, Sparano JA, Wang V, Davidson NE, Leyland-Jones BR. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene. 2015;4:129–41. doi:10.1016/j.mgene.2015.04.002.
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44. doi:10.1016/S0140-6736(11)61625-5.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72. doi:10.1016/S0140-6736(13)62422-8.
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34. doi:10.1158/1078-0432.CCR-06-1109.
   PubMed Web of Science ®Google Scholar
• Oh E, Choi YL, Park T, Lee S, Nam SJ, Shin YK. A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Res Treat. 2012;132:499–509. doi:10.1007/s10549-011-1626-8.
   PubMed Web of Science ®Google Scholar